A class of experimental cancer drugs called BET inhibitors have shown promise for treating cancers of the blood, but can induce toxic side effects. Now Yale researchers have found a new inhibitor that in animal studies demonstrates ...
Apr 16, 2020
0
829
Researchers at the University of Pennsylvania's Basser Center for BRCA at the Abramson Cancer Center have discovered factors that may make breast and ovarian cancers associated with BRCA1/2 gene mutations more likely to recur.
Nov 10, 2022
0
134
Physicians at the University of Kentucky Markey Cancer Center are the first to perform a unique procedure to treat a rare and persistent type of ovarian cancer.
Sep 19, 2017
0
128
Researchers at the Department of Obstetrics and Gynecology, Peking University Third Hospital in Beijing, China, have developed a new ovarian cancer screening technique. In a paper, "Profiling the metabolome of uterine fluid ...
Australian scientists have revealed a better way to identify which patients should respond to powerful ovarian cancer drugs called PARP inhibitors (PARPi), resolving an important question in ovarian cancer care about why ...
Sep 28, 2018
0
101
Ovarian cancer is not the most common form of cancer, but it's among the deadliest. That's because about 70 percent of cases recur. A new study by researchers at the University of Pittsburgh, UPMC Hillman Cancer Center, Magee-Womens ...
Mar 12, 2019
0
605
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Nov 17, 2015
0
996
When mutated, a gene known for its ability to repair DNA, appears to instead cause breast cancer, scientists report.
Mar 18, 2016
0
1145
Researchers from the University of Minnesota have discovered that a protein associated with metabolism, and formerly recognized as a potential therapeutic target for ovarian cancer, may instead be associated with a better ...
Jul 20, 2022
0
9
The prognosis of ovarian cancer is poor, with an estimated five-year survival of only 40% for advanced disease, the stage at which most ovarian carcinomas are diagnosed. These poor outcomes are partly due to the lack of effective ...
Feb 3, 2021
0
42
